KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cardinal Health (CAH) EBITDA (2016 - 2025)

Historic EBITDA for Cardinal Health (CAH) over the last 17 years, with Q4 2025 value amounting to $707.0 million.

  • Cardinal Health's EBITDA rose 2877.96% to $707.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.5 billion, marking a year-over-year increase of 3423.42%. This contributed to the annual value of $2.3 billion for FY2025, which is 8302.49% up from last year.
  • According to the latest figures from Q4 2025, Cardinal Health's EBITDA is $707.0 million, which was up 2877.96% from $668.0 million recorded in Q3 2025.
  • In the past 5 years, Cardinal Health's EBITDA registered a high of $730.0 million during Q1 2025, and its lowest value of -$950.0 million during Q4 2021.
  • Moreover, its 5-year median value for EBITDA was $408.0 million (2021), whereas its average is $284.6 million.
  • As far as peak fluctuations go, Cardinal Health's EBITDA plummeted by 30607.38% in 2021, and later soared by 187500.0% in 2024.
  • Quarter analysis of 5 years shows Cardinal Health's EBITDA stood at -$950.0 million in 2021, then skyrocketed by 90.95% to -$86.0 million in 2022, then soared by 687.21% to $505.0 million in 2023, then rose by 8.71% to $549.0 million in 2024, then increased by 28.78% to $707.0 million in 2025.
  • Its EBITDA was $707.0 million in Q4 2025, compared to $668.0 million in Q3 2025 and $428.0 million in Q2 2025.